HOME >> MEDICINE >> NEWS
Memorial Sloan-Kettering scientists uncover function of BRCA2 protein

NEW YORK, September 13, 2002 -- Structural biologists at Memorial Sloan-Kettering Cancer Center (MSKCC) have discovered the function of the protein BRCA2. Mutations in the BRCA2 gene have been linked to hereditary breast and ovarian cancers. The results were reported in the September 13 issue of Science.

BRCA2 was already known to be a tumor suppressor -- a protective protein that prevents the development of cancer -- but exactly how the protein does its job was not understood. Now MSKCC scientists have been able to map out the structure of the protein, showing that it interacts directly with DNA and helps to repair genetic damage. An inability to correct genetic damage leads to unstable chromosomes and often to cancer.

"If BRCA2 is altered or missing, it leads to a dangerous accumulation of genetic errors," said the study's senior author Nikola P. Pavletich, PhD, head of MSKCC's Laboratory of Structural Biology of Oncogenes and Tumor Suppressors and an investigator in the Howard Hughes Medical Institute. "By studying the normal function of BRCA2, we can understand how changes in the protein contribute to the development of cancer."

BRCA2 is an unusually large molecule, which has made it difficult for researchers to study. But Dr. Pavletich's team, including first author Haijuan Yang, found a way around that problem and was able to crystallize the protein. Those crystals were then bombarded with high-energy X-rays, a process called X-ray crystallography, and the diffraction patterns created by the X-rays were used to calculate the three-dimensional picture of the protein. This picture revealed that BRCA2 is similar in structure to other proteins known to bind DNA. The researchers then took the work a step further, showing that BRCA2 does indeed bind to DNA in special regions that are commonly found around broken DNA strands.

Researchers showed that BRCA2 participates in the repair of "double-strand" breaks: These breaks are a particularl
'"/>

Contact: Christine Hickey
Hickey1@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
12-Sep-2002


Page: 1 2

Related medicine news :

1. 2005 H. Trendley Dean Memorial Award
2. Northwestern Memorial Hospital honored with one of the nations top awards for quality
3. Northwestern Memorial physicians encourage screenings during colon cancer awareness month
4. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
5. Northwestern Memorial chosen to be featured in first-ever mini-med school TV airing on PBS
6. Countrys first simplified maze using new ultrasound technology is done at Northwestern Memorial
7. Northwestern Memorial Hospital testing new procedure for patients with major depression
8. Northwestern Memorial named one of nations top 12 hospital-affiliated infertility clinics
9. Medical College of Georgia to establish clinical campus at Phoebe Putney Memorial Hospital
10. Peter H. Arger, MD, receives the 2004 AIUM William J. Fry Memorial Lecture Award
11. Northwestern Memorial tests pacemaker for stomach

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: